n-(3-pyridylmethyl)adriamycin has been researched along with Leukemia in 2 studies
*Leukemia: A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006) [MeSH]
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Adachi, K; Collins, PW; Gutteridge, CN; Jiang, XR; Kelsey, SM; Macey, MG; Miki, T; Newland, AC; Yamabe, S | 1 |
| Adachi, K; Jenkins, GC; Jiang, XR; Macey, MG; Miki, T; Newland, AC; Yamabe, S | 1 |
2 other study(ies) available for n-(3-pyridylmethyl)adriamycin and Leukemia
| Article | Year |
|---|---|
Structure-dependent antitumor activities of novel anthracyclines YM1, YM3, YM4 and YM6: drug transport properties and effects on biomacromolecule synthesis in drug sensitive and resistant leukemia cells.
Topics: Biological Transport; DNA; Doxorubicin; Drug Resistance; Epirubicin; Humans; Leukemia; Protein Biosynthesis; RNA; Structure-Activity Relationship; Tumor Cells, Cultured | 1993 |
Evaluation of the in vitro antiproliferative properties of four novel anthracyclines YM1, 3, 4 and 6 in human leukemia cell lines.
Topics: Antineoplastic Agents; Cell Division; Doxorubicin; Drug Resistance; Drug Screening Assays, Antitumor; Epirubicin; Humans; Leukemia; Tumor Cells, Cultured | 1992 |